Compare TSLA & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSLA | GILD |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5T | 184.4B |
| IPO Year | 2010 | 2000 |
| Metric | TSLA | GILD |
|---|---|---|
| Price | $398.03 | $146.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 33 | 18 |
| Target Price | ★ $396.15 | $146.50 |
| AVG Volume (30 Days) | ★ 45.2M | 5.7M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 1.08 | ★ 6.78 |
| Revenue | ★ $94,827,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $11.02 | $4.68 |
| Revenue Next Year | $15.86 | $6.10 |
| P/E Ratio | $377.23 | ★ $21.53 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $222.28 | $95.30 |
| 52 Week High | $498.83 | $157.29 |
| Indicator | TSLA | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 51.16 |
| Support Level | $385.16 | $143.09 |
| Resistance Level | $420.34 | $157.29 |
| Average True Range (ATR) | 11.58 | 3.22 |
| MACD | 0.66 | -1.00 |
| Stochastic Oscillator | 38.05 | 37.98 |
Tesla is a vertically integrated battery electric vehicle automaker and developer of real world artificial intelligence software, which includes autonomous driving and humanoid robots. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling a sports car and offer a robotaxi service. Global deliveries in 2025 were nearly 1.64 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network and an auto insurance business.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).